Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
- Luseogliflozin in Domestic PIII Study Significantly Reduces HbA1c: Taisho Pharmaceutical
September 27, 2013
- Nippon Shinyaku, Fuji Pharma Launch Lunabell Tablets ULD
September 27, 2013
- Maruho to Turn Maeda Pharmaceutical into Subsidiary, Expand Production Capability
September 26, 2013
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
- Sanwa Kagaku, DSP to Terminate Copromotion Deal for Seibule
September 24, 2013
- Sanofi K.K. Launches GLP-1 Receptor Agonist Lyxumia
September 20, 2013
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
- Ethical Drug Sales Up 5.7% in July: Crecon Report
September 20, 2013
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…